UnitedHealth Group's Optum Rx is monitoring two drug candidates that might be approved in the next few months, according to its winter 2024 report. 

Mark Cuban Cost Plus Drug Co. will sell Euthyrox, its 21st brand-name drug, in March. 

On Feb. 23, Colorado secured a national first by agreeing to establish a price ceiling on a medication, The Denver Post reported. 

More than two and a half years after the FDA warned about an increased risk of death linked to Pepaxto, a multiple myeloma drug, the agency withdrew the medication's approval Feb. 23. 

New York Attorney General Letitia James implored the FDA Feb. 22 to update Singulair's warning label after an uptick in pediatric mental health issues linked to the asthma and allergy drug. 

Pharmaceutical giant Moderna said it anticipates initial regulatory approvals of its respiratory syncytial virus vaccine will come in the first half of 2024, according to its Q4 earnings update published Feb. 22.

The American Hospital Association is urging healthcare facilities to disconnect from Optum systemes following a cyberattack on the insurer, The Wall Street Journal reported Feb. 22.

State attorneys general are urging Congress to pass three bills that would reform pharmacy benefit manager practices and bring more transparency to their work. 

Research has shown patients often regain weight after halting use of popular weight loss drugs. But staying on medications like Ozempic and Wegovy indefinitely can be pricey. 

Grubhub has teamed up with CVS Pharmacy to deliver health and wellness products to consumers in 48 states. 

There were around 4,000 prescriptions for weight loss drugs like Wegovy and Ozempic written for U.S. patients between the ages of 12 and 18 in 2023, alone, NBC News reported Feb. 21. 

Delivering vaccines directly into the body's immune cells could make the preventions even more effective, according to new research from a pharmaceutical scientist and professor at West Virginia University in Morgantown.

As 2 in 5 hospitals report shortages of clinical pharmacists, the American Hospital Association on Feb. 20 urged the Labor Department to simplify the hiring process for immigrant pharmacists. 

Richard Gonzalez, the CEO of AbbVie since the drugmaker's inception in 2013, is exiting the role on July 1. 

 Drugmakers are pouring billions of dollars toward the advancement of treatments that target cancer more precisely than mainstay treatments like radiation and chemotherapy. 

As clinicians ration penicillin and two more cancer injectable drugs fell into shortage, supply strained recently for nearly a dozen other medications.

Roctavian held promise of treating hemophilia A, but has only been used for one patient since its approval in June 2023, Bloomberg reported Feb. 20. 

RAPT Therapeutics, a San Francisco-based pharmaceutical company, said Feb. 20 that two of its clinical trials are on pause because of one patient's liver failure. 

Mark Cuban Cost Plus Drug Co. now offers two Bayer brand-name medicines: Yaz, an oral contraceptive, and Climara, a menopause treatment. 

The American Medical Association has long been advocating against what it calls "scope creep," or nonphysicians gaining expanded scopes of practice. On Feb. 16, two pharmacist associations fired back.